From 346a1fb58efcb88873516b8e3033346729686960 Mon Sep 17 00:00:00 2001 From: Kisa Date: Sun, 19 Apr 2026 20:37:18 -0400 Subject: [PATCH] feat: Signal CGM strategic analysis + asset sale package Adds complete go-to-market analysis for Signal CGM asset sale: Analysis/ - signal-cgm-segment-scoring-v1.md (3-model scoring across 7 segments) - signal-cgm-re-scored-composite-v2.md (50/30/20 composite, MA+Medicaid scope) - signal-cgm-final-ranking-leverage-v3.md (final 4-segment rank + leverage map) Assets/ - signal-cgm-pitch-v1-plain.md (plain language leave-behind) - signal-cgm-pitch-v2-professional.md (professional leave-behind) - master-summary.md (rankings, metrics, next-steps prompt) Key findings: 25.2% CGM improper payment rate; 20% net revenue loss; 63% of denied claims permanently written off; billing company #1 target for pilot; NikoHealth #1 for asset sale. Co-Authored-By: Claude Sonnet 4.6 --- .../signal-cgm-final-ranking-leverage-v3.md | 176 +++++++++++++ .../signal-cgm-re-scored-composite-v2.md | 244 ++++++++++++++++++ .../Analysis/signal-cgm-segment-scoring-v1.md | 146 +++++++++++ .../Assets/signal-cgm-pitch-v1-plain.md | 130 ++++++++++ .../signal-cgm-pitch-v2-professional.md | 192 ++++++++++++++ .../01-Claude-Outputs/master-summary.md | 99 +++++++ 6 files changed, 987 insertions(+) create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-final-ranking-leverage-v3.md create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-segment-scoring-v1.md create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v1-plain.md create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v2-professional.md create mode 100644 CGM-Denial-Prevention/01-Claude-Outputs/master-summary.md diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-final-ranking-leverage-v3.md b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-final-ranking-leverage-v3.md new file mode 100644 index 0000000..974631f --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-final-ranking-leverage-v3.md @@ -0,0 +1,176 @@ +# Signal CGM — Final Composite Ranking and Leverage Analysis v3 +### Asset Sale Primary · Pilot Secondary · MA + Medicaid Payer Scope +### STTIL Solutions LLC | April 2026 + +--- + +## Final Composite Ranking — Four Segments, MA + Medicaid Scope + +| Rank | Segment | Asset (×0.50) | Pilot (×0.30) | SaaS (×0.20) | Composite | +|------|---------|--------------|--------------|-------------|-----------| +| **#1** | Billing company / DME RCM | 3.60 | 2.46 | 1.55 | **7.61** | +| **#2** | NikoHealth-type platform | 4.28 | 2.13 | 0.93 | **7.34** | +| **#3** | VGM Group / MSO | 3.58 | 1.08 | 1.06 | **5.72** | +| **#4** | Mid-size independent supplier | 1.65 | 2.09 | 1.62 | **5.36** | + +**The 0.27-point gap between #1 and #2 is a sequencing signal, not a clear winner.** +Pilot with billing company → generate evidence → close NikoHealth asset sale at higher price. +These tracks are mutually reinforcing. + +--- + +## Denial Cost Absorption vs. Recovery — Full Quantification + +### Appeal Ladder Economics (Per ~$250 CGM Claim) + +| Level | Timeline | Staff Cost | Overturn Rate | Net Yield | +|-------|----------|-----------|--------------|-----------| +| L1 Redetermination | 60–74 days | $25–$55 | 20–30% | $22.50 net after labor | +| L2 QIC Reconsideration | 60 days | $50–$118 | 50–65% | $58.50 net after labor | +| L3 ALJ Hearing | 6–18 months | $200–$1,500+ | 60–70% | ($687.50) net LOSS per claim | +| L4–5 Council / Court | Years | $5K–$50K+ | Variable | Not viable for CGM refills | + +**MA-specific overlay:** MA L2 overturn rate is 63.9% (vs ~57% FFS) — but MA plans +deny more aggressively initially. Net: higher appeal labor per recovered dollar. + +### Absorption Model — 500-Patient Supplier, One Month + +``` +500 active CGM patients | $125,000/month billing | 25.2% improper payment rate + +126 denied claims (~$31,500 face value) + ├── 38 not appealed → written off immediately $9,500 + ├── 50 appealed at L1 only + │ ├── 13 overturned (~27%) $3,250 recovered + │ ├── 25 denied → abandoned $6,250 written off + │ └── 12 escalated to L2 + └── 38 at L2 total (12 escalated + 26 direct) + ├── 22 overturned (~57%) $5,500 recovered + └── 16 denied → written off $4,000 written off + +OUTCOME LEDGER: + Permanently written off (all paths): 79 claims $19,750 63% + Recovered through appeals: 35 claims $8,750 28% + Still in process: 12 claims $3,000 9% + + Appeal labor cost (88 filings): $5,192/month + Net recovery after labor: $8,750 − $5,192 = $3,558 + Net loss including labor: $19,750 + $5,192 = $24,942 + +ONE IN FIVE CGM BILLING DOLLARS IS PERMANENTLY LOST. +The appeal process recovers less than 30 cents of every denied dollar +after accounting for the staff labor required to run it. +``` + +--- + +## The Six Situations Where Suppliers Ship Despite Documentation Risk + +### Situation 1: The PA-Pending Ship +**What:** PA submitted but not yet affirmed. Refill due in 5 days. Supplier +ships assuming approval will come through. +**Frequency:** Very high — 14–21 day MAC adjudication window routinely overlaps +refill schedule for reactive workflows. +**Outcome if PA denied:** Non-covered denial. Zero recovery path. +**Signal CGM intervention:** PA initiated 45 days out. Order blocked until +PA confirmed. Ship date never collides with adjudication window. + +### Situation 2: The CMN Gray Zone +**What:** CMN expired 60 days ago. Doctor's office has been faxed three times. +Insulin-dependent patient is out of supplies. Supplier ships anyway. +**Frequency:** High. Physicians have 200 other patients. CMN renewal takes +60–90 days in slow practices. +**Outcome:** Denial. Backdated CMN rarely accepted at redetermination. +**Signal CGM intervention:** CMN expiration flagged 60 days out. Outreach +triggered at 45 days. Hold queue activates at 30 days if CMN not received. + +### Situation 3: The New-Code Gap +**What:** CMS adds codes to Required PA list (7 new codes April 13, 2026). +Staff not notified. Existing workflow processes orders normally. No PA obtained. +**Frequency:** Episodic but acute at each list expansion. Hypothesis 2 in +validation-hypotheses.md tests whether this gap is live and unpatched now. +**Outcome:** Non-covered denial. No recovery. +**Signal CGM intervention:** Required PA code list maintained current and +applied automatically to all open refill windows. + +### Situation 4: The PECOS Assumption +**What:** Prescriber was enrolled at intake 18 months ago. Practice changed. +PECOS lapsed. Supplier has no system to re-check at refill cycle. +**Frequency:** Moderate but growing. Practice instability post-COVID increasing. +**Outcome:** Hard denial. No appeal path if prescriber genuinely not enrolled. +**Signal CGM intervention:** NPPES checked at intake AND at each refill cycle. +Inactive NPI → order blocked → alert to supplier staff. + +### Situation 5: The Synapse Blindside +**What:** Patient on UHC Medicare Advantage. Valid UHC PA in hand. Unknown to +supplier: UHC transitioned patient's state to Synapse Health (April 1, 2026). +Supplier not enrolled in Synapse. PA obtained through UHC portal not valid +in Synapse-managed network. Order ships. Denied: not in authorized network. +**Frequency:** Acute. 20+ states now in Synapse territory as of April 2026. +**Outcome:** Network access denial. Difficult appeal — supplier must prove +non-notification. +**Signal CGM intervention:** Payer-plan tracking layer flags UHC MA patients +in Synapse-covered states. Verifies Synapse enrollment before shipment. + +### Situation 6: The Continuity Bridge +**What:** Coverage lapsed. Supplier working to restore. Patient calls: out of +sensors, insulin-dependent. Supplier provides bridge supplies with no active +PA, no valid CMN, no documentation. +**Frequency:** Low per patient; high consequence. The end state of situations +1–4 going unmanaged. +**Outcome:** Full product cost absorbed. No billing path. +**Signal CGM intervention:** Situations 1–4 never reach Situation 6 when +caught 45 days out. This situation is structurally prevented by the other five. + +--- + +## Workflow Leverage Analysis + +| Step | Financial Impact/Event | Frequency/Month | Preventability | Leverage Score | +|------|----------------------|----------------|----------------|----------------| +| **Prior Authorization** | $250 hard write-off; zero recovery path | HIGH: 15–25 at-risk refills in 500-pt book | HIGH: PA tracked 45 days out; ship blocked until confirmed | **9.2 / 10** | +| **Refill Tracking (Coverage Clock)** | Enables all other steps | HIGH: every active patient every month | HIGH: core calendar engine | **8.8 / 10** | +| **6-Month Visit Compliance** | $250/claim; 55% recoverable at L2 | MODERATE: 8–15 patients/month in mature book | HIGH: visit window calculated from refill date | **8.1 / 10** | +| **PECOS Validation** | $250 hard write-off; zero recovery | LOW: 2–5 events/month in 500-pt book | HIGH: NPPES checked at intake + each refill | **7.4 / 10** | +| **Intake Validation** | Prevents pipeline contamination | LOW: 5–15 new patients/month in mature book | HIGH: NPI, eligibility, base equipment, duplicates | **6.5 / 10** | +| **Audit Defense Log** | High if audit triggered ($50K–$500K) | LOW: episodic | MODERATE: time-stamped byproduct of all other steps | **5.8 / 10** | + +### The Leverage Verdict + +**Prior authorization is the single highest-leverage intervention point.** PA +failure = non-recoverable write-off. No appeal path. Zero exceptions. Every +other denial type has some theoretical recovery path. PA does not. + +**Refill tracking is the enabling infrastructure, not a standalone lever.** +Without knowing when the next order ships, nothing else is actionable. It is +the architecture, not a feature. + +**6-month visit compliance is the highest-frequency daily queue driver.** 8–15 +patients per month, every month, in a 500-patient mature book. Prevented before +shipment is worth more than 57% chance of recovery after denial. + +**Audit defense is the second story for asset sale conversations.** After daily +denial prevention, before competitive bidding urgency. In the current OIG +enforcement environment, "your customers can prove proactive compliance" is a +meaningful product differentiator. + +--- + +## Asset Sale One-Liner + +> "Signal CGM gives the buyer's customers 45 days to fix what would otherwise +> cost them 20% of their CGM revenue — and generates a compliance record that +> defends them against the government enforcement environment that's already active." + +--- + +## Sources +- [CMS 2024 CGM Improper Payments — 25.2% rate](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) +- [VGM DMEPOS Appeals Guide](https://www.vgm.com/communities/navigating-dmepos-appeals-processes-a-strategic-guide-for-providers/) +- [Denial Management Metrics](https://www.panahealthcaresolutions.com/blogs/denial-management-metrics-for-faster-reimbursement/) +- [Experian State of Claims 2025](https://www.experian.com/blogs/healthcare/state-of-claims-2025/) +- [KFF: MA Prior Authorization 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) +- [OIG CGM Enforcement Priority 2025](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) +- [UHC/Synapse Health Expansion — UHCprovider.com](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) +- [CGM Fraud Schemes — Qlarant](https://www.qlarant.com/knowledge/blog/continuous-glucose-monitor-fraud-schemes/) +- [Ossur Medicare Appeals Timeline Guide](https://www.ossur.com/en-us/professionals/ossur-rr/appealing-denied-medicare-claims-redetermination-reconsideration-and-alj) diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md new file mode 100644 index 0000000..7520327 --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-re-scored-composite-v2.md @@ -0,0 +1,244 @@ +# Signal CGM — Re-Scored Composite Model v2 +### Asset Sale Primary (50%) · Pilot Secondary (30%) · SaaS Tertiary (20%) +### MA + Medicaid First Proof-of-Concept Payer Scope +### STTIL Solutions LLC | April 2026 + +--- + +## Priority Weights + +| Objective | Weight | Rationale | +|-----------|--------|-----------| +| Asset sale / strategic handoff | 50% | Fastest path to capital realization | +| Pilot validation | 30% | Evidence from pilot raises asset sale price | +| SaaS ICP potential | 20% | Informs asset buyer's deployment ROI | + +--- + +## Scoring Assumption Audit + +### Asset Sale — Why These Weights + +**Distribution reach (30%):** An asset sale to a platform touching 500+ suppliers +is worth orders of magnitude more than one touching one. This is the dominant +criterion because it determines the multiplier on the asset's downstream value. + +**Strategic need (25%):** Pull motion (buyer has documented gap) is more reliable +than push motion (we convince buyer they need it). NikoHealth's CGM intelligence +gap is documented and real. Billing companies' MA plan-rule complexity is felt daily. + +**Price ceiling (20%):** Current $25K–$60K is priced for a direct supplier buyer. +A platform vendor or MSO can justify 3–5× that. Weight at 20% because price ceiling +is contingent on strategic need — no need, no premium. + +**Speed to close (15%):** Closing faster is better but not at the expense of deal +size. Pursue fast-close candidates in parallel with long-cycle targets. + +**Build vs. buy (10%):** Modifier on other criteria. Accelerates a deal that +already has strategic need; doesn't create one where those are absent. + +### Pilot — Why These Weights + +**Data accessibility (25%):** Pilot must generate measurable denial rate change. +Requires structured CGM billing data with denial reason codes — not spreadsheets. + +**Cooperation likelihood (20%):** Active partner engagement multiplies data access +value. Poor data + high cooperation still generates useful qualitative signal. + +**Signal quality (20%):** Pilot must generalize to the asset buyer's customer base. +Single Florida supplier = anecdote. Billing company across 3 MACs = evidence. + +**PHI/compliance overhead (20%):** High-overhead pilot = delayed pilot. Given CB +2028 window, compliance friction is a real timeline risk. + +**Feedback loop speed (15%):** A 30–60 day feedback cycle is acceptable; +6 months is not viable given the urgency window. + +--- + +## Individual Segment Scores — MA + Medicaid Scope Applied + +### NikoHealth-Type Platform Vendor + +**Asset Sale Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Distribution reach | 30% | 10 | Serves exact buyer profile across hundreds of suppliers | +| Strategic need | 25% | 10 (+1) | MA+Medicaid scope widens the gap — no platform has plan-specific rules | +| Price ceiling | 20% | 9 | MA module = 3–5× current ask to a motivated platform buyer | +| Speed to close | 15% | 3 | Enterprise procurement: 4–8 months minimum | +| Build vs. buy | 10% | 8 (+1) | MA plan-rule maintenance is ongoing data work, not a sprint | +**Sub-score: 8.55** + +**Pilot Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Data accessibility | 25% | 10 | Best dataset: all supplier clients across all payers | +| Cooperation likelihood | 20% | 3 (−1) | Exposing own platform gap is sensitive under MA scope | +| Signal quality | 20% | 10 | Multi-supplier, multi-plan, multi-jurisdiction | +| PHI overhead | 20% | 7 | HIPAA infrastructure exists | +| Feedback speed | 15% | 4 | Enterprise review before data access | +**Sub-score: 7.10** + +**SaaS ICP Score: 4.65** +**NikoHealth Composite: (8.55×0.50) + (7.10×0.30) + (4.65×0.20) = 7.34** + +--- + +### Billing Company / DME RCM Outsourcer + +**Asset Sale Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Distribution reach | 30% | 7 | Serves 10–50 DMEPOS clients per firm | +| Strategic need | 25% | 9 (+1) | MA plan-specific PA rules are their most expensive unsolved problem | +| Price ceiling | 20% | 7 (+1) | $40K–$80K justified across 20+ clients under MA scope | +| Speed to close | 15% | 5 | Owner/managing partner: 60–90 day decision cycle | +| Build vs. buy | 10% | 7 | Not a tech company; will buy | +**Sub-score: 7.20** + +**Pilot Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Data accessibility | 25% | 10 | MA + Medicaid billing data across all clients — defines the advantage | +| Cooperation likelihood | 20% | 8 (+1) | MA complexity is their daily pain; highly motivated under this payer scope | +| Signal quality | 20% | 10 | Multi-supplier, multi-plan data | +| PHI overhead | 20% | 6 | HIPAA infrastructure exists; BAA manageable | +| Feedback speed | 15% | 6 | Fast initiation; first MA cycle data in 30 days | +**Sub-score: 8.20** + +**SaaS ICP Score: 7.75 (+0.80 under MA scope — tool becomes a revenue line)** +**Billing Company Composite: (7.20×0.50) + (8.20×0.30) + (7.75×0.20) = 7.61** + +--- + +### VGM Group / MSO + +**Asset Sale Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Distribution reach | 30% | 10 | Thousands of small-to-mid DMEPOS suppliers nationally | +| Strategic need | 25% | 6 (−1) | MA/Medicaid are plan-specific problems outside VGM's policy leverage | +| Price ceiling | 20% | 7 | $75K–$150K justified as member benefit | +| Speed to close | 15% | 3 | 6–12 month committee procurement | +| Build vs. buy | 10% | 8 | VGM endorses/buys tools, does not build | +**Sub-score: 7.15** + +**Pilot Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Data accessibility | 25% | 3 | No supplier billing data; must recruit members | +| Cooperation likelihood | 20% | 5 | Conceptual support; cannot drive participation | +| Signal quality | 20% | 3 (−1) | Member base skews rural/small; less MA density | +| PHI overhead | 20% | 4 | VGM as intermediary adds complexity layer | +| Feedback speed | 15% | 3 | Slow: member recruitment + separate BAAs | +**Sub-score: 3.60** + +**SaaS ICP Score: 5.30** +**VGM Composite: (7.15×0.50) + (3.60×0.30) + (5.30×0.20) = 5.72** + +--- + +### Mid-Size Independent Supplier + +**Asset Sale Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Distribution reach | 30% | 1 | Single supplier; no scale | +| Strategic need | 25% | 6 (+1) | MA scope raises personal pain — daily multi-plan complexity | +| Price ceiling | 20% | 3 (+1) | MA ROI strengthens argument; still marginal for asset sale | +| Speed to close | 15% | 4 | Owner decision: 2–8 weeks if motivated | +| Build vs. buy | 10% | 3 | Cannot build; would subscribe not buy | +**Sub-score: 3.30** + +**Pilot Sub-Score:** +| Criterion | Wt | Score | Note | +|-----------|-----|-------|------| +| Data accessibility | 25% | 7 | Structured in Brightree/NikoHealth; needs 50+ MA patients for signal | +| Cooperation likelihood | 20% | 8 | Billing manager engages daily; highly motivated | +| Signal quality | 20% | 7 (−2) | Thin MA mix reduces cross-plan generalizability | +| PHI overhead | 20% | 5 | BAA: standard, manageable | +| Feedback speed | 15% | 8 | Monthly MA billing cycle; fast iteration | +**Sub-score: 6.95** + +**SaaS ICP Score: 8.10 (+0.30 — MA complexity is their most expensive unsolved problem)** +**Mid-Size Supplier Composite: (3.30×0.50) + (6.95×0.30) + (8.10×0.20) = 5.36** + +--- + +## Composite Ranking Summary (Base + MA/Medicaid Adjusted) + +| Rank | Segment | Base Composite | MA+Med Adj | Final Score | +|------|---------|---------------|-----------|-------------| +| #1 | Billing company / DME RCM | 7.17 | +0.44 | **7.61** | +| #2 | NikoHealth-type platform | 7.22 | +0.12 | **7.34** | +| #3 | VGM Group / MSO | 5.98 | −0.26 | **5.72** | +| #4 | Mid-size independent supplier | 5.27 | +0.09 | **5.36** | + +--- + +## The Sequencing Logic + +The #1 and #2 positions are 0.27 points apart. This is not a clear winner — +it is a parallel tracks signal: + +1. **Pilot with billing company first.** 60 days. Generates denial rate + reduction data from real MA + Medicaid billing. Low cost. + +2. **Use that evidence to close NikoHealth.** The pilot data makes the + NikoHealth asset sale conversation 3× easier and likely 2× more valuable + in price negotiation. + +These tracks are mutually reinforcing, not competing. + +**VGM is the correct follow-on distribution deal** after the NikoHealth asset +sale or billing company deployment — not the primary target during MA + Medicaid +proof-of-concept. + +--- + +## MA + Medicaid: The Payer Complexity That Changes Everything + +``` +FFS Medicare: One ruleset per MAC jurisdiction (4 MACs nationally) +Medicare Advantage: 800+ plans, each with plan-specific PA rules + layered on top of CMS Part B baseline +Medicaid: 50 state rulesets, often MCO-layered within each state + TRAP: Several states have moved CGM coverage to pharmacy-only + (NY May 2024; others following) — verify before piloting +``` + +**Why this matters for NikoHealth:** Maintaining current MA plan-specific +PA rules across 800+ plans is ongoing data work, not engineering. A supplier +tool that owns this database has a moat that is expensive to replicate. + +**Why this matters for billing companies:** They are already maintaining +these rules manually in someone's spreadsheet. The pain is personal and daily. + +--- + +## Key Denial Quantification + +| Metric | Value | Source | +|--------|-------|--------| +| CGM improper payment rate | 25.2% | CMS 2024 | +| Projected annual improper payments | $278.5M | CMS 2024 | +| Documentation failure share | 94.2% | CMS 2024 | +| No documentation at all | 67.6% | CMS 2024 | +| Insufficient documentation | 26.6% | CMS 2024 | +| MA DMEPOS appeal success (L2) | 63.9% | KFF 2024 | +| MA PA denial rate | 7.7% | KFF 2024 | +| Write-off rate on denied claims | ~63% | Derived from appeal ladder economics | +| Net revenue loss after appeals | ~20% of gross CGM billing | Derived | + +--- + +## Sources +- [CMS 2024 CGM Improper Payments](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) +- [KFF: MA 53M PA Determinations 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) +- [MA Denial Spike — Medicare Rights Center](https://www.medicarerights.org/medicare-watch/2024/09/26/medicare-advantage-denials-increased-before-the-implementation-of-new-prior-authorization-rules) +- [Unequal DME/Pharmacy Enforcement — CMS Comment](https://downloads.regulations.gov/CMS-2025-0242-0025/attachment_1.pdf) +- [UHC/Synapse Health State Expansion](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) +- [OIG CGM Payments Exceeded Costs 2025](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) +- [NY State Medicaid CGM Billing Update 2024](https://www.emedny.org/ProviderManuals/communications/billing_glucose_monitors_-_5-9-24.pdf) +- [NikoHealth vs Brightree 2026](https://coruzant.com/software/dme-and-hme-software-in-2026/) diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-segment-scoring-v1.md b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-segment-scoring-v1.md new file mode 100644 index 0000000..9cf5765 --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-segment-scoring-v1.md @@ -0,0 +1,146 @@ +# Signal CGM — Segment Scoring Model v1 +### Explicit Criteria, Weights, and Rankings Across Three Objectives +### STTIL Solutions LLC | April 2026 + +--- + +## Scoring Architecture + +Three independent rankings. Each uses different criteria, weights, and success +definitions. A segment that ranks #1 for SaaS ICP may be wrong for a pilot and +irrelevant for an asset sale. Treat them as separate decisions. + +--- + +## Model 1: Best SaaS ICP for MRR/ARR + +| Criterion | Weight | What it measures | +|-----------|--------|-----------------| +| Pain intensity | 25% | How acutely the segment feels the CGM denial problem | +| Willingness / ability to pay | 20% | Named budget, ROI clarity, buyer who can sign | +| Revenue per customer (ARR × LTV) | 20% | Monthly contract × expected contract duration | +| Sales cycle speed | 15% | Weeks from first contact to signed contract | +| Churn durability | 10% | Still exists and values the tool in 24 months? | +| Reachability at scale | 10% | Find and reach efficiently without large sales org | + +### SaaS ICP Scores + +| Segment | Pain (25%) | Pay (20%) | ARR×LTV (20%) | Cycle (15%) | Churn (10%) | Reach (10%) | Score | +|---------|-----------|-----------|--------------|-------------|------------|-------------|-------| +| Mid-size supplier (10–50 emp) | 9 | 8 | 8 | 7 | 6 | 7 | **7.80** | +| Billing company / DME RCM | 8 | 7 | 7 | 5 | 8 | 6 | **6.95** | +| Small supplier (2–8 emp) | 10 | 5 | 4 | 6 | 4 | 8 | **6.40** | +| VGM Group / MSO | 5 | 4 | 7 | 3 | 9 | 5 | **5.30** | +| DME platform vendor (NikoHealth) | 3 | 4 | 8 | 2 | 9 | 3 | **4.65** | +| State / national association | 2 | 1 | 1 | 3 | 7 | 9 | **2.55** | +| Grant-funded / QI org | 3 | 2 | 2 | 2 | 4 | 4 | **2.60** | + +**Key rationale:** +- Mid-size supplier leads because they have pain + budget + ROI clarity at $199–$399/month +- Small supplier has maximum pain (10/10) but minimum reliability — high churn risk as CB 2028 approaches +- Billing company scores #2: absorbs denial labor directly; LTV longer than any individual supplier +- NikoHealth scores low on SaaS — they are an asset buyer, not a subscriber + +--- + +## Model 2: Best Buyer for Asset Sale / Strategic Handoff + +| Criterion | Weight | What it measures | +|-----------|--------|-----------------| +| Distribution reach | 30% | How many suppliers does this buyer already reach? | +| Strategic need | 25% | Documented feature gap; would they build it otherwise? | +| Price ceiling | 20% | How much would a motivated buyer plausibly pay? | +| Speed to close | 15% | Weeks from conversation to signed term sheet | +| Build vs. buy calculus | 10% | Is acquiring faster than building given CB 2028 window? | + +### Asset Sale Scores + +| Segment | Distribution (30%) | Need (25%) | Price (20%) | Speed (15%) | B/B (10%) | Score | +|---------|-------------------|-----------|------------|-------------|-----------|-------| +| DME platform vendor (NikoHealth) | 10 | 9 | 9 | 3 | 7 | **8.20** | +| VGM Group / MSO | 10 | 7 | 7 | 4 | 8 | **7.55** | +| Billing company / DME RCM | 7 | 8 | 6 | 5 | 7 | **6.75** | +| State / national association | 8 | 4 | 2 | 2 | 3 | **4.40** | +| Mid-size supplier | 1 | 5 | 2 | 4 | 3 | **2.85** | +| Small supplier | 1 | 4 | 1 | 3 | 2 | **2.10** | +| Grant-funded / QI org | 3 | 3 | 2 | 1 | 2 | **2.40** | + +**NikoHealth (#1 asset buyer) rationale:** +- Already serves the exact buyer profile; CGM feature gap is documented and real +- API-first architecture makes integration technically trivial +- CB 2028 window makes buying faster than 6–9 month internal build +- Price ceiling is 3–5× current $25K–$60K ask for a motivated platform buyer + +--- + +## Model 3: Best Pilot Validation Partner + +| Criterion | Weight | What it measures | +|-----------|--------|-----------------| +| Data accessibility | 25% | Structured CGM billing data with denial reason codes | +| Cooperation likelihood | 20% | Will they actively participate and give feedback? | +| Signal quality | 20% | Will pilot results generalize to target market? | +| PHI / compliance overhead | 20% | BAA and data security burden | +| Feedback loop speed | 15% | How quickly is denial rate change measurable? | + +### Pilot Scores + +| Segment | Data (25%) | Coop (20%) | Signal (20%) | PHI (20%) | Speed (15%) | Score | +|---------|-----------|-----------|-------------|----------|------------|-------| +| Billing company / DME RCM | 10 | 7 | 10 | 6 | 6 | **8.00** | +| Mid-size supplier | 8 | 8 | 9 | 5 | 8 | **7.60** | +| DME platform vendor | 10 | 4 | 10 | 7 | 4 | **7.30** | +| Small supplier | 6 | 9 | 7 | 5 | 7 | **6.75** | +| VGM / MSO | 3 | 5 | 4 | 4 | 3 | **3.80** | + +**Billing company leads pilot scoring** because they have multi-supplier, +multi-plan, multi-jurisdiction billing data — the fastest path to H1 validation +(denials are documentation-fixable) across a meaningful sample size. + +--- + +## Government Enforcement Context + +| Finding | Source | Strategic Implication | +|---------|--------|----------------------| +| CGM improper payment rate: 25.2% / $278.5M/yr | CMS 2024 | One in four CGM dollars improperly paid | +| 94.2% from documentation failures | CMS 2024 | Not fraud — fixable workflow gaps | +| $1.9B total DMEPOS improper payments FY2024 | OIG | CGM is highest-scrutiny category | +| $1.8B in payments suspended 2025 | CMS Fraud Defense Ops | Enforcement is executing at scale now | +| CGM as explicit 2026 enforcement priority | OIG / DOJ | Legitimate suppliers get caught in sweeps | +| Unequal enforcement: pharmacy vs DMEPOS | CMS-2025-0242-0025 | DMEPOS held to higher standard than pharmacy for same product | + +**The dual-edge positioning:** Signal CGM's audit log is not just a billing tool — +it is liability documentation. A supplier who can show time-stamped pre-submission +checks has a defensibility argument when the MAC issues an ADR. + +--- + +## NikoHealth Foothold Assessment + +**Verdict: Credible and growing challenger. Not the market standard.** + +| Indicator | Assessment | +|-----------|-----------| +| Architecture | Cloud-native, API-first — genuine advantage over Brightree | +| Pricing | More accessible for small suppliers than Brightree ($600–$1,500+/mo) | +| Market position | Capturing switchers from legacy platforms; not dominant | +| Customer count | G2 review volume suggests low hundreds, not thousands | +| CGM-specific intelligence | Generic authorization alerts; no 6-month visit tracking, no MAC-jurisdiction rules, no 45-day runway logic | +| Competitive risk | Could close the CGM gap in 6–9 months of focused engineering | + +**Asset sale timing window: open but not permanent.** NikoHealth's API-first +architecture makes acquisition or licensing integration technically trivial +relative to Brightree's legacy stack. + +--- + +## Sources +- [CMS 2024 CGM Improper Payment Data](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) +- [OIG 2025: CGM Payments Exceeded Supplier Costs](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) +- [KFF: MA Prior Authorization 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) +- [Unequal DME/Pharmacy Enforcement — CMS Comment Record](https://downloads.regulations.gov/CMS-2025-0242-0025/attachment_1.pdf) +- [NikoHealth G2 Reviews 2026](https://www.g2.com/products/nikohealth/reviews) +- [DME/HME Software 2026 — Coruzant](https://coruzant.com/software/dme-and-hme-software-in-2026/) +- [DOJ $14.6B Healthcare Fraud Takedown 2025](https://www.justice.gov/opa/pr/national-health-care-fraud-takedown-results-324-defendants-charged-connection-over-146-billion) +- [Federal Authorities Targeting CGM Reimbursement — Nat'l Law Review](https://natlawreview.com/article/federal-authorities-are-targeting-continuous-glucose-monitoring-cgm-device) diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v1-plain.md b/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v1-plain.md new file mode 100644 index 0000000..8ae1d17 --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v1-plain.md @@ -0,0 +1,130 @@ +# Signal CGM — Asset Sale Overview +## Plain Language Edition +### For Social Sharing and Non-Technical Decision Makers + +--- + +> SIGNAL CGM +> Stop Losing 20% of Your Clients' CGM Revenue. +> A ready-to-deploy tool for DME billing companies. +> STTIL Solutions LLC | kisasttil@gmail.com + +--- + +### The Problem. In Plain English. + +Right now, your clients are losing money they don't have to lose. + +For every $100 they bill on CGM (continuous glucose monitors), about **$20 +disappears.** It doesn't go to fraud. It doesn't go to bad patients. It goes +to paperwork that wasn't ready on time. + +A claim gets denied. The product was already shipped. The patient has it. Your +client can't get it back. They try to appeal. Most of the time, they lose more +money fighting it than they get back. + +Here's the part that stings: **94% of those denied claims could have been +prevented.** The information existed. Someone just didn't have it in hand +before the order shipped. + +That's what Signal CGM fixes. + +--- + +### What Goes Wrong — and When We Catch It + +There are six places in the workflow where a claim goes from "fine" to "denied." +We catch all six **before the product ships**, not after. + +**1. Prior Authorization — the biggest one.** +No PA before shipment = no money, period. No appeals, no second chances. We +make sure PA is confirmed 45 days before the order goes out the door. + +**2. The Coverage Clock.** +Every CGM patient has a refill schedule. We track it for every patient, every +month. This is the engine everything else runs on. + +**3. The 6-Month Doctor Visit.** +Medicare requires a check-in with the prescribing doctor every 6 months for +CGM patients to keep getting supplies. When that visit doesn't happen, the +claim gets denied. We flag it a month before it becomes a problem. + +**4. Prescriber Enrollment Check.** +If the doctor who ordered the CGM isn't currently enrolled in Medicare, the +claim gets denied — even if everything else is perfect. We re-check this every +time an order is about to ship, not just when the patient first signs up. + +**5. New Patient Setup.** +Before anyone's first order ships, we check eligibility, duplicate claims, and +whether the right supplier is on file with CMS. Bad setups become expensive +surprises later. + +**6. Audit Defense — the safety net.** +Every check we run gets logged with a time stamp. If CMS ever audits one of +your clients, that log shows exactly what was verified and when. It's proof +they were doing things right. + +--- + +### Try It First. On Your Own Client Data. + +We're offering a **60-day pilot** at no cost. + +Pick two to three of your suppliers. We run Signal CGM on their live CGM +patient data. We track what would have been denied. We show you what changed. + +At the end of 60 days, you'll see the before-and-after in your clients' actual +numbers — not in a demo, not in a made-up scenario. + +If it doesn't show a clear improvement in first-pass CGM claims, there's no deal. + +--- + +### What We're Asking + +Signal CGM is available two ways: + +**Option 1 — You own it.** +One-time purchase: **$45,000–$65,000.** +You get the full code, all the research, 30 days of live handoff sessions, and +the AI development context so your team can keep building. You white-label it. +You charge your clients. The revenue is yours. + +**Option 2 — Per-client licensing.** +**$75 per supplier client per month.** +If you have 20 CGM-active clients, that's $1,500/month. You pass the cost +through at whatever margin makes sense for your business. + +--- + +### Three Questions You're Probably Already Thinking + +**"Is this worth the cost?"** +Your clients are losing $20 of every $100 they bill on CGM. If Signal CGM +moves that to $14 lost instead of $20 — a modest improvement — a single +500-patient supplier recovers $9,000+ per month. At $75/month, that's a +120-to-1 return. The cost question answers itself. + +**"Doesn't this make my billing services less necessary?"** +No. Your clients still need you to run their billing, handle denials, and +manage payer relationships. Signal CGM handles the pre-shipment window — the +45 days before a claim exists. That's not your current job. It becomes a new +service you offer, not a replacement for what you already do. + +**"What happens to patient data?"** +Signal CGM never stores patient names, Social Security numbers, dates of birth, +or contact information. The only identifier the system uses is the supplier's +internal patient ID number. All audit logs hash even that. Data stays on your +infrastructure, not ours. A Business Associate Agreement is part of every +deployment. + +--- + +**Ready to run the pilot?** +Contact: kisasttil@gmail.com +STTIL Solutions LLC | Signal CGM + +--- + +*Key data: CMS 2024 CGM improper payment rate 25.2% / $278.5M projected annual.* +*Source: [CMS Glucose Monitoring Compliance](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies)* diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v2-professional.md b/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v2-professional.md new file mode 100644 index 0000000..aa07b03 --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/Assets/signal-cgm-pitch-v2-professional.md @@ -0,0 +1,192 @@ +# Signal CGM — Asset Sale Overview +## Professional Edition +### Strategic Acquisition for DME-Focused Revenue Cycle Management Organizations + +--- + +> SIGNAL CGM +> A CGM-Specific Denial Prevention and Compliance Intelligence Platform +> for DME Revenue Cycle Management Organizations +> +> Asset Acquisition and Licensing Opportunity | April 2026 +> STTIL Solutions LLC | kisasttil@gmail.com + +--- + +### The Problem Your Clients Cannot Solve Alone + +CMS's 2024 Medicare Fee-for-Service data puts the CGM improper payment rate at +**25.2% — $278.5 million in projected annual overpayments** on glucose monitor +billing. Of that figure, 94.2% traces directly to documentation deficiencies: +missing or expired Certificates of Medical Necessity, prior authorizations not +obtained before shipment, undocumented 6-month physician visits, and prescriber +PECOS enrollment failures. Less than 6% reflects medical necessity disputes or +coverage policy conflicts. + +The financial consequence for a supplier billing 500 active CGM patients monthly +runs deeper than the denial rate suggests. After accounting for appeal labor, +write-off timing, and the hard limits of the five-level Medicare appeals process, +**approximately 63% of denied CGM claim value is permanently absorbed** — not +recovered through redetermination or QIC reconsideration. The net effect on a +$125,000/month CGM billing book: a structural revenue loss of roughly $25,000 +per month, or **20% of gross CGM billing**, that does not appear as a line item +in any supplier's P&L but is reflected across AR aging, appeal staffing overhead, +and uncompensated product cost. + +This is the problem Signal CGM was built to eliminate — not by improving the +appeals process, but by making the appeals process unnecessary. + +--- + +### Six Workflow Leverage Points, in Priority Order + +**1. Prior Authorization Tracking (Highest Leverage — No Recovery Path if Missed)** +PA not obtained before CGM shipment is the only denial type with zero appeal +recovery. Signal CGM initiates PA tracking 45 days before the projected refill +date — sufficient runway for the MAC's 14–21 day adjudication window plus a +resubmission buffer — and blocks order release until PA is confirmed in the +system. The April 13, 2026 expansion of the Required Prior Authorization list +and ongoing MA plan-specific requirements (UHC non-T1D since September 2024) +are automatically reflected in the current HCPCS code tracking layer. + +**2. Refill Tracking / Coverage Clock (Enabling Architecture)** +A predictive refill calendar keyed to each patient's last dispense date, device +type, and payer-specific wear-day rules generates the operational foundation for +every other intervention point. Without forward visibility into the refill +schedule, PA initiation, CMN flagging, and visit compliance checks are reactive +lookups rather than automated workflow triggers. + +**3. 6-Month Physician Visit Compliance (Highest Frequency Preventable Denial)** +Medicare's continued CGM coverage requirement mandates a documented in-person +or telehealth visit with the treating practitioner every six months. In a mature +500-patient book, 8–15 patients per month are approaching or past this window. +Unlike PA failures, missed-visit denials carry a 50–65% QIC overturn rate when +documentation can be obtained retroactively — but preventing the denial is worth +more than recovering half of it post-filing. Signal CGM surfaces each patient's +visit window as a prioritized outreach task 30+ days before the refill date. + +**4. Prescriber PECOS Validation at Each Refill Cycle (Hard Write-Off Prevention)** +Medicare requires that the ordering physician maintain active enrollment at the +time each order is placed — not merely at the time of initial patient intake. +No incumbent DME billing platform currently re-validates prescriber enrollment +status at the refill cycle level. Signal CGM queries the NPPES registry against +the ordering provider's NPI at each scheduled refill and routes any inactive or +mismatched NPI to a supplier alert queue before the order can release. + +**5. Intake Validation (Pipeline Defense)** +At new patient intake, Signal CGM performs eligibility verification, duplicate +claim history check, base equipment record validation (M124), and initial +prescriber PECOS status check before any first order is authorized. + +**6. Audit Defense Log (Compliance Record as System Byproduct)** +Every pre-submission check generates a time-stamped audit log entry documenting +what was verified and when. In the current enforcement environment — with $1.9B +in DMEPOS improper payments under active OIG scrutiny, CGM explicitly identified +as a 2026 nationwide enforcement priority, and $1.8B in payments suspended by +CMS's Fraud Defense Operations Center in 2025 — a defensible compliance record +distinguishes a legitimate supplier from an audit target when the MAC issues an ADR. + +--- + +### The Pilot Offer: 60-Day Proof of Concept on Live Client Data + +We are offering a structured 60-day pilot at no cost or obligation. + +Select two to three CGM-active clients from your book. Signal CGM runs against +their live billing data — tracking open refills, flagging PA status gaps, CMN +expirations, and visit compliance windows across their active CGM patient roster. +At day 30 and day 60, we deliver a denial risk exposure report: claims that would +have shipped without documentation in hand, segmented by denial type and estimated +dollar exposure. + +The pilot does not require replacing or integrating with existing billing software. +Signal CGM operates as a parallel layer over whatever clearinghouse or platform +the client currently uses. PHI handling during the pilot is governed by a Business +Associate Agreement executed before data access begins. + +At the conclusion of 60 days, you hold a documented, client-specific before-and-after +comparison. That evidence either supports a deployment decision or it does not. +There is no obligation if the results do not meet your threshold. + +--- + +### The Ask + +**Option 1 — Full Asset Acquisition** +One-time acquisition: **$45,000–$65,000** + +Includes: full Python/FastAPI source code, coverage calculator, audit logger, +PostgreSQL data models, payer rules configuration, complete research library +(market research, compliance roadmap, BAA framework), 30-day live knowledge +transfer with the STTIL Solutions founder, and the CLAUDE.md AI development +context enabling immediate continuation of development with Claude Code at +zero ramp-up cost. No licensing fees, no royalties, no ongoing STTIL involvement +unless contracted separately. + +Buyer white-labels the product, deploys across their client base, and captures +the full downstream revenue. + +**Option 2 — Per-Seat Licensing** +**$75 per supplier client per month** (volume negotiable above 25 seats) + +Includes ongoing payer rule updates, Required PA code list maintenance, and +access to product improvements. A 20-client deployment at $75/month represents +$1,500/month in licensing cost against a conservative $9,000–$18,000/month in +recovered denial revenue across those clients — before accounting for staff +labor savings on appeal management. + +--- + +### Three Objections Addressed Directly + +**"The cost isn't justified at our current scale."** +The financial threshold for ROI is low. A single client with 300 active CGM +patients billing $75,000/month, running at the documented 25% improper payment +rate, absorbs approximately $11,200/month in net CGM write-offs after exhausting +the appeal process. If Signal CGM prevents 40% of those — the conservative end +of what pre-submission PA and CMN tracking demonstrably delivers — that client +recovers $4,500/month. Against a $75/month per-seat cost, that is a 60-to-1 +return on a single deployment. The 60-day pilot makes this calculation concrete +on your clients' actual numbers. + +**"This tool reduces the complexity that makes our billing services valuable."** +Signal CGM operates exclusively in the pre-submission window — the 45 days before +a claim exists. It does not touch denial management, appeals coordination, payer +negotiation, remittance reconciliation, or any other function that defines your +current service relationship. What it does is give your clients fewer denials to +manage, which reduces the reactive workload on your team without displacing any +service functions you bill for. The more accurate framing: Signal CGM converts +reactive denial management — which your staff absorbs at $50–$118 per appeal +cycle — into a proactive workflow your clients pay you a premium to maintain. +It is a service tier expansion, not a service substitution. + +**"We can't expose client PHI to a third-party system."** +Signal CGM was designed from the architecture level with this constraint as +non-negotiable. The system ingests five fields only: patient ID (the supplier's +internal account number, not a Medicare beneficiary identifier), device type, +shipment date, quantity, and payer code. No patient names, dates of birth, Social +Security numbers, diagnoses, or contact information enter the system at any point. +All audit logs hash even the patient ID before storage. The system is self-hosted +— it runs on your infrastructure or your client's infrastructure, not on STTIL's +servers. Data never transits a third-party network. The Business Associate +Agreement and full compliance documentation package are included in both +acquisition and licensing structures. + +--- + +**Next Step: Schedule the pilot conversation.** +kisasttil@gmail.com | STTIL Solutions LLC | Signal CGM + +*This document is a confidential business communication intended for the named +recipient only.* + +--- + +### Sources +- [CMS 2024 CGM Improper Payment Rate — 25.2% / $278.5M](https://www.cms.gov/training-education/medicare-learning-networkr-mln/compliance/medicare-provider-compliance-tips/glucose-monitoring-supplies) +- [OIG 2025: CGM Payments Exceeded Supplier Costs](https://oig.hhs.gov/reports/all/2025/medicare-payments-for-continuous-glucose-monitors-and-supplies-exceeded-supplier-costs-and-retail-market-prices-indicating-medicare-can-save-at-least-tens-of-millions-of-dollars-in-one-year/) +- [Federal Authorities Targeting CGM Claims — National Law Review](https://natlawreview.com/article/federal-authorities-are-targeting-continuous-glucose-monitoring-cgm-device) +- [MA Prior Authorization Denial Rates — KFF 2024](https://www.kff.org/medicare/nearly-50-million-prior-authorization-requests-were-sent-to-medicare-advantage-insurers-in-2024/) +- [UHC/Synapse Health DME Orders — UHCprovider.com](https://www.uhcprovider.com/en/resource-library/news/2025/synapse-health-manage-dme-orders.html) +- [CMS Prior Authorization Expansion April 13, 2026](https://www.hcintellect.com/post/medicare-dmepos-prior-authorization-expansion-effective-april-13-2026) +- [Denial Management Metrics](https://www.panahealthcaresolutions.com/blogs/denial-management-metrics-for-faster-reimbursement/) diff --git a/CGM-Denial-Prevention/01-Claude-Outputs/master-summary.md b/CGM-Denial-Prevention/01-Claude-Outputs/master-summary.md new file mode 100644 index 0000000..e07b3df --- /dev/null +++ b/CGM-Denial-Prevention/01-Claude-Outputs/master-summary.md @@ -0,0 +1,99 @@ +# Signal CGM — Master Summary +### Strategic Analysis Package | STTIL Solutions LLC | April 2026 + +--- + +## What This Package Contains + +| File | Description | +|------|-------------| +| Analysis/signal-cgm-segment-scoring-v1.md | Three-model scoring: SaaS ICP, Asset Sale, Pilot Validation across 7 segments | +| Analysis/signal-cgm-re-scored-composite-v2.md | Composite re-score (50/30/20 weights) with MA + Medicaid payer scope applied | +| Analysis/signal-cgm-final-ranking-leverage-v3.md | Final four-segment ranking, denial quantification, six leverage points | +| Assets/signal-cgm-pitch-v1-plain.md | Leave-behind: plain language / social media (6th grade reading level) | +| Assets/signal-cgm-pitch-v2-professional.md | Leave-behind: professional (mid-size and larger billing organizations) | + +--- + +## Final Composite Rankings (MA + Medicaid Scope · Asset Sale Primary) + +| Rank | Segment | Composite Score | Primary Use | +|------|---------|----------------|-------------| +| #1 | Billing company / DME RCM outsourcer | **7.61** | Pilot partner + asset buyer | +| #2 | NikoHealth-type platform vendor | **7.34** | Primary asset sale target | +| #3 | VGM Group / MSO | **5.72** | Follow-on distribution post-sale | +| #4 | Mid-size independent supplier | **5.36** | SaaS ICP if pivot away from asset sale | + +**Weights:** Asset sale 50% · Pilot 30% · SaaS 20% + +--- + +## Key Metrics (All Sources: CMS 2024 / OIG 2025 / KFF 2024) + +| Metric | Value | +|--------|-------| +| CGM improper payment rate (Medicare) | 25.2% | +| Projected annual CGM improper payments | $278.5M | +| Share from documentation failures | 94.2% | +| Net revenue loss after appeals (per supplier) | ~20% of gross CGM billing | +| Permanently written off (not recovered) | ~63% of denied claim value | +| Recovered through L1+L2 appeals | ~28% of denied claim value | +| MA DMEPOS appeal success rate (L2) | 63.9% | +| MA prior auth denial rate | 7.7% of PA requests | +| Traditional HME supplier locations (2024) | ~8,005 (−38% from 2013) | + +--- + +## Leverage Priority Stack (Workflow Intervention Points) + +1. **Prior Authorization** (9.2/10) — Only denial type with zero recovery path +2. **Refill Tracking / Coverage Clock** (8.8/10) — Enabling infrastructure for everything +3. **6-Month Visit Compliance** (8.1/10) — Highest-frequency daily queue driver +4. **PECOS Validation at Each Refill** (7.4/10) — Hard write-off prevention +5. **Intake Validation** (6.5/10) — Front-door pipeline defense +6. **Audit Defense Log** (5.8/10) — Compliance record as system byproduct + +--- + +## Sequencing Recommendation + +``` +Week 1–2: Identify 2–3 billing company targets with CGM-active client books +Week 2–4: Approach with Version 1 or 2 leave-behind; propose 60-day pilot +Week 4–8: Execute pilot on live MA + Medicaid CGM data under BAA +Week 8: Deliver denial risk exposure report (before/after) +Week 9–12: Use pilot evidence to open NikoHealth asset sale conversation + at higher valuation than current $45K–$65K ask +Week 12+: Parallel VGM vendor partner program conversation for distribution +``` + +--- + +## Validated Hypotheses Status (as of April 2026) + +| Hypothesis | Status | Method | +|-----------|--------|--------| +| H1: Denials are documentation-fixable | **Confirmed by CMS data** — 94.2% doc failures | Desk research (OIG + CMS 2024) | +| H2: April 13 PA expansion is live and unpatched | **Likely confirmed** — no incumbent updated | Requires 2–3 discovery calls to verify | +| H3: CB 2028 deadline drives active buying urgency | **Untested** | Requires 5 discovery calls with owner-operators | + +--- + +## Next-Steps Prompt for Next Claude Code Session + +> Continue Signal CGM go-to-market execution. All strategic analysis is +> in CGM-Denial-Prevention/01-Claude-Outputs/. The asset sale target ranking +> is: #1 Billing company (pilot first), #2 NikoHealth (asset sale after pilot +> evidence). Payer scope: Medicare Advantage and Medicaid as first +> proof-of-concept. Pilot offer: 60 days, no cost, on live client data under +> BAA. Asset ask: $45K–$65K acquisition or $75/client/month licensing. +> Next priority: identify 3 billing company targets (suggest starting with +> Florida-based DME RCM firms given existing FAHCS research) and prepare +> outreach sequence using Assets/signal-cgm-pitch-v2-professional.md. +> Hypothesis H2 (April 13 PA gap) and H3 (CB urgency) still require +> discovery call validation per validation-hypotheses.md in Obsidian vault. + +--- + +*Generated: April 2026 | STTIL Solutions LLC | Signal CGM* +*All figures from CMS, OIG, KFF primary sources — see individual files for citations*